文档介绍：拉米夫定联合卡托普利治疗166例慢性乙型肝炎患者的抗肝纤维化疗效分析
作者:李春明,黄晓云,金跃明,龚玉华,谭友文
【摘要】目的研究联合使用抗病毒药物和血管紧张素转换酶抑制剂治疗慢性乙型肝炎抗肝纤维化疗效。方法回顾性分析单纯降酶治疗、单用拉米夫定、卡托普利、联合拉米夫定和卡托普利治疗一年的166例慢性乙型肝炎患者的临床资料,比较治疗前后肝纤维化血清标志物及肝组织纤维化分期变化情况评价不同治疗方案的抗肝纤维化疗效。结果联合用药组、拉米夫定组、卡托普利组治疗后血肝纤4项水平与治疗前相比有不同程度降低,治疗后肝组织均显示S0~1期比例明显增加,S2~3期、S4期比例显著下降,而降酶组治疗前后肝纤四项水平及肝组织纤维化分期差异无统计学意义。结论使用拉米夫定、卡托普利治疗慢性乙型肝炎均有抗肝纤维化作用,联合使用效果更加明显。
【关键词】慢性乙型肝炎肝纤维化拉米夫定卡托普利
Abstract: Objective To study the effect of inhibiting fibrosis bination treatment with Lamivudine and Captopril on CHB (chronic hepatitis B).Methods 166 cases with CHB, who were divided into reducing-liver enzyme group, Lamivudine group, Captopril group bination group with Lamivudine and Captopril according to different therapeutic strategy used on them, were analyzed retrospectively. And the levels of four blood markers and histologic stages on hepatic fibrosis of these cases were The levels of the four blood markers declined in varying degrees after pared with those before treatment bination group, Lamivudine group, and Captopril group respectively. At the same time, the rates of histologic stage 0-1 rose remarkably, while the rates of stage 2-3 and stage 4 descended markedly. There were not significant statistic difference between in the levels of the four blood markers and histologic stages in reducing-liver enzyme group before and after Both Lamiv